Reschke, M., D. Mihic-Probst, E. H. van der Horst, P. Knyazev, P. J. Wild, M. Hutterer, S. Meyer, R. Dummer, H. Moch and A. Ullrich: HER3 is a determinant for poor prognosis in melanoma. In: Clinical Cancer Research 14, 16, 5188-5197 (2008).
van der Horst, E. H., M. Murgia, M. Treder and A. Ullrich: Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. In: International Journal of Cancer 115, 4, 519-527 (2005).
van der Horst, E. H., I. Weber and A. Ullrich: Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: Novel heregulin/HER3-stimulated signaling pathway in glioma. In: International Journal of Cancer 113, 5, 689-698 (2005).
van der Horst, E. H., J. H. Leupold, R. Schubbert, A. Ullrich and H. Allgayer: TaqMan((R))-based quantification of invasive cells in the chick embryo metastasis assay. In: BioTechniques 37, 6, 940-946 (2004).
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.